Table 3. Acute rejections during the study period.
| Rejection factors | Sirolimus | Control | P value |
|---|---|---|---|
| Biopsy proven acute rejection | 9 (32.1%) | 18 (26.1%) | 0.546 |
| TCMR | 9 | 15 | |
| AMR | 0 | 1 | |
| Mixed rejection | 0 | 2 | |
| Time to first BPAR, day (median, range) | 61 (5-373) | 29 (5-175) | 0.455 |
| Anti-rejection treatment | |||
| Antibody therapy* | 3 (33.3%) | 4 (22.2%) | 0.653 |
| Therapeutic plasmapheresis | 1 (11.1%) | 2 (11.1%) | >0.99 |
*Antithymocyte globulin (ATG). TCMR, T cell mediated rejection; AMR, antibody-mediated rejection; BPAR, Biopsy proven acute rejection.